You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 7, 2025

Drug Price Trends for AMINOCAPROIC ACID


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for AMINOCAPROIC ACID

Average Pharmacy Cost for AMINOCAPROIC ACID

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
AMINOCAPROIC ACID 0.25 GRAM/ML 69315-0503-24 1.14772 ML 2025-01-22
AMINOCAPROIC ACID 0.25 GRAM/ML 31722-0035-23 1.14772 ML 2025-01-22
AMINOCAPROIC ACID 0.25 GRAM/ML 69238-1596-08 1.14772 ML 2025-01-22
AMINOCAPROIC ACID 500 MG TAB 72205-0049-30 2.00692 EACH 2025-01-22
AMINOCAPROIC ACID 1,000 MG TAB 24658-0799-30 10.53314 EACH 2025-01-22
AMINOCAPROIC ACID 0.25 GRAM/ML 52817-0815-08 1.14772 ML 2025-01-22
AMINOCAPROIC ACID 0.25 GRAM/ML 70377-0104-11 1.14772 ML 2025-01-22
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for AMINOCAPROIC ACID

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Unit Dates Price Type
AMINOCAPROIC ACID 1000MG TAB Nationwide Pharmaceutical LLC 69315-0232-03 30 856.89 28.56300 EACH 2022-05-25 - 2026-04-30 FSS
AMINOCAPROIC ACID 1000MG TAB Akorn, Inc. 17478-0769-30 30 406.99 13.56633 EACH 2020-08-01 - 2025-05-14 FSS
AMICAR 250MG/ML SOLN, ORAL Akorn, Inc. 49411-0052-08 236.5ML 1688.16 7.13810 ML 2022-01-01 - 2025-05-14 FSS
AMINOCAPROIC ACID 250MG/ML SOLN,ORAL Akorn, Inc. 17478-0447-08 236.5ML 217.85 0.92114 ML 2023-01-01 - 2025-05-14 FSS
AMICAR 500MG TAB Akorn, Inc. 49411-0050-30 30 428.11 14.27033 EACH 2023-01-01 - 2025-05-14 FSS
AMINOCAPROIC ACID 1000MG TAB Akorn, Inc. 17478-0769-30 30 384.71 12.82367 EACH 2021-01-01 - 2025-05-14 FSS
AMICAR 250MG/ML SOLN, ORAL Akorn, Inc. 49411-0052-08 236.5ML 1826.59 7.72342 ML 2023-01-01 - 2025-05-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Unit >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for Aminocaproic Acid

Introduction to Aminocaproic Acid

Aminocaproic acid, commonly known by its brand name Amicar, is a member of the miscellaneous coagulation modifiers drug class. It is primarily used to treat fibrinolytic bleeding, a condition where the body's natural processes to dissolve blood clots are overly active, leading to excessive bleeding.

Market Size and Growth Projections

The global market for aminocaproic acid is experiencing significant growth and is poised for continued expansion. Here are some key points:

  • Market Size and Forecast: The aminocaproic acid market is expected to see substantial growth from 2023 to 2031, with projections indicating a remarkable CAGR during this period. The market size is measured in USD million and is segmented by type (tablets, solution), application (hospital, clinic, other), and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa)[1][4].

  • Segmentation: The market is categorized based on type (10ml, 20ml for injections; tablets, solution for oral forms) and application (hospital, clinic, other). Geographical regions also play a crucial role in market segmentation[1][4].

  • Growth Drivers: The upward trajectory in market dynamics is driven by increasing regulatory approvals, rising awareness for the treatment of blood-related disorders, and the commercialization of approved antifibrinolytic drugs. For instance, recent FDA approvals for generic versions of aminocaproic acid tablets and oral solutions have boosted market growth[3][4].

Market Dynamics

Drivers

  • Regulatory Approvals: Recent approvals from the U.S. Food and Drug Administration (FDA) for generic versions of aminocaproic acid have significantly driven market growth. Companies like Amneal Pharmaceuticals, Inc. and ANI Pharmaceuticals, Inc. have received approvals, expanding the market[3][4].

  • Increasing Awareness: Rising awareness about the treatment of angioedema and other blood-related disorders is creating lucrative opportunities for the market[3].

Restraints

  • Product Recalls: Potential product recalls can hamper market growth. Any safety issues or manufacturing defects leading to recalls can negatively impact market dynamics[3].

  • Stock Shortages: Stock shortages and other unknown variables can affect pricing and availability, which might restrain market growth[2][5].

Opportunities

  • Expanding Applications: The use of aminocaproic acid in various medical fields such as gynecology (to prevent menorrhagia), surgeries, and fibrinolytic response testing presents significant opportunities for market expansion[3].

  • Partnerships and Collaborations: Partnerships between companies to develop and commercialize antifibrinolytic drugs are expected to enhance market presence and growth[3].

Price Analysis

The prices of aminocaproic acid vary based on the form and dosage of the drug.

Oral Tablets

  • 500 mg Tablets: The cost for aminocaproic acid 500 mg oral tablets can range from $192 to $821 for a supply of 30 tablets, depending on the pharmacy and any discounts applied[2][5].

  • 1000 mg Tablets: For 1000 mg tablets, the price range is from $355 to $1,255 for a supply of 30 tablets[2][5].

Oral Liquid

  • 1.25 g/5 mL: The cost for aminocaproic acid oral liquid (1.25 g/5 mL) can range from $619 to $2,860 for 236.5 milliliters[2][5].

Intravenous Solution

  • 250 mg/mL: The price for aminocaproic acid intravenous solution (250 mg/mL) can range from $150 to $249 for 500 milliliters[2].

Regional Analysis

The global aminocaproic acid market is segmented into several geographical regions, each with its own market dynamics.

  • North America: This region is expected to be a significant market due to advanced healthcare infrastructure and high regulatory standards.
  • Europe: Europe also holds a substantial share of the market, driven by increasing demand for antifibrinolytic drugs.
  • Asia-Pacific: This region is anticipated to show rapid growth due to expanding healthcare needs and increasing regulatory approvals[1][4].

Key Players

The market includes both established and emerging players. Some notable companies include:

  • Amneal Pharmaceuticals, Inc.: Known for receiving FDA approval for the generic version of Amicar (aminocaproic acid oral solution)[3].
  • ANI Pharmaceuticals, Inc.: Received FDA approval for Aminocaproic Acid Tablets USP, 500mg[3].
  • Sunny Pharmtech, Inc.: Announced the approval of their ANDA for Aminocaproic Acid Tablets[3].

Consumer Behavior and Economic Impact

Consumer behavior is influenced by the availability of generic versions and the overall cost-effectiveness of the drug. The economic impact is significant, as the market's growth contributes to the overall healthcare economy.

Challenges and Opportunities

Challenges

  • Regulatory Hurdles: Ensuring compliance with regulatory standards can be challenging and may affect market growth.
  • Competition: The presence of other antifibrinolytic drugs like tranexamic acid can pose competition to aminocaproic acid[3].

Opportunities

  • Research and Development: Continuous R&D in antifibrinolytic drugs can lead to new applications and improved formulations.
  • Market Expansion: Expanding into new geographical regions and increasing awareness about the drug can open up new market opportunities[3].

Key Takeaways

  • The aminocaproic acid market is expected to experience significant growth from 2023 to 2031.
  • Regulatory approvals and increasing awareness about blood-related disorders are key drivers.
  • The market is segmented by type, application, and geographical regions.
  • Prices vary widely depending on the form and dosage of the drug.
  • Key players include Amneal Pharmaceuticals, Inc., ANI Pharmaceuticals, Inc., and Sunny Pharmtech, Inc.

FAQs

Q: What is aminocaproic acid used for? Aminocaproic acid is used to treat fibrinolytic bleeding, a condition where the body's natural processes to dissolve blood clots are overly active, leading to excessive bleeding[2].

Q: What are the different forms of aminocaproic acid available? Aminocaproic acid is available in various forms, including oral tablets (500 mg and 1000 mg), oral liquid (1.25 g/5 mL), and intravenous solution (250 mg/mL)[2].

Q: How much does aminocaproic acid cost? The cost of aminocaproic acid varies widely depending on the form and dosage. For example, 500 mg oral tablets can cost between $192 to $821 for 30 tablets, while the oral liquid can cost between $619 to $2,860 for 236.5 milliliters[2][5].

Q: What are the key drivers of the aminocaproic acid market? Key drivers include recent FDA approvals for generic versions, rising awareness about blood-related disorders, and the commercialization of approved antifibrinolytic drugs[3][4].

Q: Which regions are expected to show significant growth in the aminocaproic acid market? North America, Europe, and the Asia-Pacific region are expected to show significant growth due to advanced healthcare infrastructure, increasing demand, and expanding healthcare needs[1][4].

Sources

  1. Market Research Intellect - Global Aminocaproic Acid Injection Market Size, Trends and Projections
  2. Drugs.com - Aminocaproic acid Prices, Coupons, Copay Cards & Patient Assistance
  3. Meta Stat Insight - Antifibrinolytic Drugs Market Size, Share, Growth, Forecast by 2027
  4. Market Research Intellect - Global Aminocaproic Acid Market Size, Trends and Projections
  5. Drugs.com - Amicar Prices, Coupons, Copay Cards & Patient Assistance

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.